Key result
Combination antihypertensive therapy was initiated in nearly 25% of older adults, with Black patients significantly more likely to receive it than white patients (PR 1.48; 95% CI 1.45-1.51).
Why the study?
What factors predict the initiation of combination antihypertensive therapy versus monotherapy in older Americans without prevalent cardiovascular disease?
Cohort (n=275,493)
Yes
What factors predict the initiation of combination antihypertensive therapy versus monotherapy in older Americans without prevalent cardiovascular disease?
Nearly one in four older Americans initiating antihypertensive therapy start with combination therapy, with significant demographic and healthcare utilization predictors such as Black race and seeing multiple doctors.
Racial differences in initial regimens merit monitoring; leaves open whether combination therapy improves outcomes versus monotherapy in older adults without CVD.
OBJECTIVES: To describe new users of antihypertensive medications and identify predictors of combination therapy initiation in older Americans. DESIGN: Retrospective observational cohort study. SETTING: Population-based study using U.S. Medicare fee-for-service healthcare claims (2007-2010). PARTICIPANTS: Medicare beneficiaries aged 65 and older with no recent diagnoses, procedures, or medications for cardiovascular disease who newly initiated an antihypertensive therapy (n = 275,493; 210,605 initiated monotherapy, 64,888 initiated combination therapy). MEASUREMENTS: Multivariable Poisson regression was used to assess factors associated with initiation of combination therapy versus monotherapy, including participant characteristics, prescriber characteristics, and participant encounters with the healthcare system. RESULTS: Initiation of combination therapy increased from 21.9% in 2007 to 24.7% in 2010. The most frequently initiated combinations were angiotensin-converting enzyme inhibitors with thiazide (29.7%) and angiotensin II receptor antagonists with thiazide (18.7%). Blacks (prevalence ratio (PR) = 1.48, 95% confidence interval (CI) = 1.45-1.51 vs. whites), individuals seeing a generalist (PR = 1.10, 95% CI = 1.07-1.14), individuals seeing more than one doctor (PR = 3.38, 95% CI = 3.33-3.44), and participants with no pharmacy claims in the previous 6 months (PR = 1.34, 95% CI = 1.30-1.37 vs. ≥3 unique drug classes) were more likely to initiate combination therapy, whereas those who had more outpatient visits in the previous 12 months were less likely to initiate combination therapy (per five visits, PR = 0.82, 95% CI = 0.80-0.83). CONCLUSION: Nearly one in four new users of antihypertensive medications aged 65 and older started treatment with combination therapy. Blacks, individuals living in the south, and those with fewer outpatient physician office visits were more likely to initiate combination therapy. Further research is needed to determine whether this approach to managing hypertension is being well targeted to individuals who will require combination treatment.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) conducted a cohort in Hypertension (n=275,493). Combination antihypertensive therapy vs. Monotherapy was evaluated on Initiation of combination therapy (PR 1.48, 95% CI 1.45-1.51). Combination antihypertensive therapy was initiated in nearly 25% of older adults, with Black patients significantly more likely to receive it than white patients (PR 1.48; 95% CI 1.45-1.51).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: